Estimating the clinical cost of drug development for orphan versus non-orphan drugs-Reference-Cited by-同舟云学术

Estimating the clinical cost of drug development for orphan versus non-orphan drugs

Published:2019-01-10 Issue:1 Volume:14 Page:
ISSN:1750-1172
Container-title:Orphanet Journal of Rare Diseases
language:en
Short-container-title:Orphanet J Rare Dis

Author:

Jayasundara Kavisha,Hollis Aidan,Krahn Murray,Mamdani Muhammad,Hoch Jeffrey S.,Grootendorst Paul

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Genetics (clinical),General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13023-018-0990-4.pdf

Reference22 articles.

1. Kumar Kakkar A, Dahiya N. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space. Drug Dev Res. 2014;75(4):231–4.

2. Field MJ, B.T., editors, Rare Diseases and Orphan Products: Accelerating Research and Development. 2010, Washington (DC): National Academies Press (US).

3. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.

4. EvaluatePharma, Orphan Drug Report 2017. 2017.

5. Haffner ME, Torrent-Farnell J, Maher PD. Does orphan drug legislation really answer the needs of patients? Lancet. 2008;371(9629):2041–4.

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Benefit and Revenues of Drugs Affected by Rare Pediatric Disease Priority Review Vouchers, 2017-2023;The Journal of Pediatrics;2024-12

2. Using Artificial Intelligence to Advance the Research and Development of Orphan Drugs;Businesses;2024-09-09

3. Bedside manufacturing as the next step in personalized medicine: medical progress and legal challenges;Journal of Law and the Biosciences;2024-07

4. Quantifying Research and Development Expenditures in the Drug Industry;JAMA Network Open;2024-06-28

5. Costs of Drug Development and Research and Development Intensity in the US, 2000-2018;JAMA Network Open;2024-06-28